

WHATCOM CAPITAL II CORP.

(A Capital Pool Company)

MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED NOVEMBER 30, 2025 AND 2024

(Expressed in Canadian dollars unless otherwise stated)

Introduction

The following management discussion and analysis ("MD&A"), prepared as at January 29, 2026, should be read in conjunction with Whatcom Capital II Corp.'s (the "Company", "Whatcom") unaudited condensed interim consolidated financial statements and the accompanying notes for the nine months ended November 30, 2025 and 2024 and the audited consolidated financial statements and accompanying notes for the years ended February 28, 2025 and February 29, 2024. The unaudited condensed interim consolidated financial statements for the nine months ended November 30, 2025 and 2024 have been prepared in accordance with IAS 34 and International Financial Reporting Standards ("IFRS"). Except as otherwise disclosed, all dollar figures included therein and in the following MD&A are quoted in Canadian dollars. For further information on the Company reference should be made to the Company's public filings which are available on SEDAR+.

Description of Business

The Company was incorporated under the Business Corporations Act (British Columbia) on January 14, 2021 and is classified as a capital pool company as defined in Policy 2.4 of the TSX Venture Exchange Inc. (the "TSX-V"). The Company's principal business is the identification and evaluation of assets or a business (the "Qualifying Transaction") and, once identified or evaluated, to negotiate an acquisition or participation in a business subject to receipt of shareholder approval, if required, and acceptance by regulatory authorities. The Company's registered and head office address is 750-1095 West Pender Street, Vancouver, B.C. V6E 2M6. There is no assurance that the Company will identify a Qualifying Transaction within the time limitations permissible under the policies of the Exchange, at which time the Exchange may suspend or delist the Company's shares from trading.

Letter of Intent

On September 22, 2022, the Company announced it entered into a letter of intent (the "LOI") with Terrazero Technologies Inc. ("Terrazero") regarding a proposed transaction to acquire all of the issued and outstanding securities of Terrazero (the "Transaction"). Upon completion of the Transaction, the combined entity (the "Resulting Issuer") was to continue the business of Terrazero. The Transaction was intended to constitute the Company's "Qualifying Transaction", as such a term is defined in Policy 2.4 - "Capital Pool Companies" of the TSX Venture Exchange (the "Exchange"). Pursuant to the proposed transaction, on January 13, 2023, the Company incorporated 1396032 B.C. Ltd., a wholly-owned subsidiary of the Company. On February 1, 2023, the Company entered into a definitive business combination agreement ("Definitive Agreement") with Terrazero. In June 2023, the Company terminated the Definitive Agreement with respect to the Transaction. The Company will recommence its identification and evaluation of other prospective business opportunities in order to complete the QT.

Initial Public Offering

During the year ended February 28, 2022, the Company filed a prospectus dated May 28, 2021 with the securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan and Ontario. On July 27, 2021, the Company completed its initial public offering ("IPO") in which it distributed 7,550,000 common shares of the Company at a price of \$0.10 per common share for aggregate gross proceeds of \$755,000 pursuant to the final prospectus dated May 28, 2021. The Company's common shares were listed on July 27, 2021 and commenced trading on the TSX Venture Exchange (the "Exchange") on July 29, 2021 under the trading symbol "WAT.P". Haywood Securities Inc. (the "Agent") acted as exclusive agent in respect of the IPO on a commercially reasonable efforts basis. Pursuant to the IPO, the Agent received a cash commission of 10% of the gross proceeds raised and an aggregate of 755,000 non-transferable common share purchase warrants entitling the Agent and members of its selling group to purchase 755,000 common shares at \$0.10 per common share at any time until July 27, 2023. On July 27, 2023 these warrants expired unexercised. The Agent also received a cash corporate finance fee in the amount of \$10,000. At the closing of the IPO, the Company also granted stock options (the "Options") to certain directors of the Company to acquire up to an aggregate of 800,000 common shares.

Each Option is exercisable to acquire one common share at a price of \$0.10 any time prior to July 27, 2026. Following completion of the IPO, the Company had 15,000,000 common shares issued and outstanding, 7,630,000 of which are subject to escrow restrictions pursuant to the policies of the Exchange.

As at November 30, 2025, the Company had a deficit of \$429,057 (February 28, 2025 – \$415,656), which has been funded by the issuance of equity. These consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in these consolidated financial statements.

Selected Financial Data - Summary of Quarterly Results

The following selected financial information is derived from the unaudited interim consolidated financial statements prepared in accordance with IFRS.

	Nov 30, 2025 \$	Aug 31, 2025 \$	May 31, 2025 \$	Feb 28, 2025 \$
Interest income	16,303	464	473	557
General and administrative expenses	(11,180)	(11,676)	(7,785)	(19,735)
Net and comprehensive income (loss)	5,123	(11,212)	(7,312)	(19,178)
Basic and diluted income (loss) per share	0.00	(0.00)	(0.00)	(0.00)
Working capital	663,030	657,907	669,119	676,431
Total assets	663,071	669,036	679,827	693,041
Non-current liabilities	-	-	-	-

	Nov 30, 2024 \$	Aug 31, 2024 \$	May 31, 2024 \$	Feb 29, 2024 \$
Interest income	5,306	7,000	7,000	-
General and administrative expenses	(8,407)	(16,226)	(6,315)	(21,347)
Net and comprehensive income (loss)	(3,101)	(9,226)	685	(21,347)
Basic and diluted income (loss) per share	(0.00)	(0.00)	0.00	(0.00)
Working capital	695,609	698,710	707,936	707,251
Total assets	696,081	705,263	710,908	721,255
Non-current liabilities	-	-	-	-

Three months ended November 30, 2025 compared to the three months ended November 30, 2024

During the three months ended November 30, 2025 (the “Q3-2026 Quarter”), the Company incurred a net and comprehensive income of \$5,123 compared to a net and comprehensive loss of \$3,101 for the three months ended November 30, 2024 (the “Q3-2025 Quarter”). During the Q3-2026 Quarter, general and administrative expense included the following: \$6,300 (Q3-2025 Quarter - \$6,300) for rent, \$2,830 (Q3-2025 Quarter - \$1,339) for filing fees and transfer agent, \$2,500 (Q3-2025 Quarter - \$768) for office expenses and \$450 recovery (Q3-2025 Quarter - \$Nil) for professional fees. The Company was relatively inactive during the Q3-2026 and Q3-2025 Quarters incurring primarily compliance related costs. During the Q3-2026 Quarter, the Company earned \$16,303 (Q3-2025 - \$5,306) in interest income and was included in cash and cash equivalents.

Three months ended November 30, 2024 compared to the three months ended November 30, 2023

During the three months ended November 30, 2024 (the “Q3-2025 Quarter”), the Company incurred a net and comprehensive loss of \$3,101 compared to a net and comprehensive loss of \$22,742 for the three months ended November 30, 2023 (the “Q3-2024 Quarter”).

During the Q3-2025 Quarter, general and administrative expense included the following: \$6,300 (Q3-2024 Quarter - \$8,000) for rent, \$1,339 (Q3-2024 Quarter - \$3,137) for filing fees and transfer agent, \$768 (Q3-2024 Quarter - \$998) for office expenses and \$Nil (Q3-2024 Quarter - \$10,607) for professional fees.

The Company was relatively inactive during the Q3-2025 and Q3-2024 Quarters incurring primarily compliance related costs. During the Q3-2025 Quarter, the Company earned \$5,306 (Q3-2024 - \$Nil) in interest income and was included in cash and cash equivalents.

Nine months ended November 30, 2025 compared to nine months ended November 30, 2024

During the nine months ended November 30, 2025 (the “YTD-2026 Period”), the Company incurred a net and comprehensive loss of \$13,401 compared to a net and comprehensive loss of \$11,642 for the nine months ended November 30, 2024 (the “YTD-2025 Period”). During the YTD-2026 Period, general and administrative expense included the following: \$18,900 (YTD-2025 Period - \$18,900) for rent, \$8,976 (YTD-2025 Period - \$4,550) for filing fees and transfer agent, \$2,557 (YTD-2025 Period - \$823) for office expenses and \$208 (YTD-2025 Period - \$6,675) for professional fees. During the YTD-2026 Period, the Company earned \$17,240 (YTD-2025 Period - \$19,306) in interest income and was included in cash and cash equivalents.

Nine months ended November 30, 2024 compared to nine months ended November 30, 2023

During the nine months ended November 30, 2024 (the “YTD-2025 Period”), the Company incurred a net and comprehensive loss of \$11,642 compared to a net and comprehensive loss of \$68,097 for the nine months ended November 30, 2023 (the “YTD-2024 Period”). During the YTD-2025 Period, general and administrative expense included the following: \$18,900 (YTD-2024 Period - \$20,000) for rent, \$4,550 (YTD-2024 Period - \$6,292) for filing fees and transfer agent, \$823 (YTD-2024 Period - \$1,489) for office expenses and \$6,675 (YTD-2024 Period - \$40,316) for professional fees. During the YTD-2025 Period, the Company earned \$19,306 (Q3-2024 - \$Nil) in interest income and was included in cash and cash equivalents.

Financial Condition / Capital Resources

At November 30, 2025, the Company had a net working capital of \$663,030 (February 28, 2025 – \$676,431), cash and cash equivalents of \$661,603 (February 28, 2025 – \$687,171), current liabilities of \$41 (February 28, 2025 – \$16,610) and had a deficit of \$429,057 (February 28, 2025 – \$415,656).

Cash Flows

Net cash and cash equivalents used in operating activities during the nine months ended November 30, 2025 was \$25,568 (2024 - \$24,528). The cash and cash equivalents used in operating activities for the current year consists primarily of the operating income (loss) and changes in non-cash working capital accounts.

During the nine months ended November 30, 2025 and 2024, investing and financing activities did not provide any cash inflows or outflows.

Financings and Related

During the nine months ended November 30, 2025 and 2024, the Company did not issue any common shares.

On January 14, 2021, the Company issued 4,000,000 common shares at \$0.05 per share to the directors of the Company for proceeds of \$200,000.

On February 22, 2021, the Company completed a financing by issuing 3,450,000 common shares at \$0.05 per share for proceeds of \$172,500.

On July 27, 2021, the Company completed its IPO and issued 7,550,000 common shares (“Shares”) of the Company at a price of \$0.10 per Share for aggregate gross proceeds of \$755,000. Haywood Securities Inc. (the “Agent”) acted as exclusive agent in respect of the IPO. Pursuant to the IPO, the Agent received a cash commission of 10% of the gross proceeds raised and an aggregate of 755,000 non-transferable common share purchase warrants entitling the Agent and members of its selling group to purchase 755,000 common shares at \$0.10 per common share at any time until July 27, 2023. On July 27, 2023 these warrants expired unexercised. The Agent also received a cash corporate finance fee in the amount of \$10,000 and legal fees of \$20,000.

The fair value of the 755,000 Agent Warrants was \$53,856 and was estimated using the Black-Scholes pricing model with the following assumptions:

Risk free interest rate	1.48%
Expected life	2 years
Expected volatility	149%
Expected dividends	0%

Stock Options

On January 14, 2021, the Company adopted an incentive stock option plan (the “Option Plan”) which allows the Company’s Board of Directors, at its discretion and in accordance with TSX Venture Exchange requirements, to grant options to directors, officers and consultants for up to 10% of the issued and outstanding common shares. The options can be granted for a maximum term of ten years and vest at the discretion of the board of directors. The Company did not grant and stock options during the nine months ended November 30, 2025 and 2024. On July 27, 2021, the Company issued 800,000 stock options to directors of the Company at an exercise price of \$0.10 and expire on July 27, 2026. The fair value of the 800,000 stock options was \$71,542 and was estimated using the Black-Scholes pricing model with the following assumptions:

Risk free interest rate	2.14%
Expected life	5 years
Expected volatility	142%
Expected dividends	0%

The following table summarizes stock option transactions:

	Number of options	Weighted average exercise price \$
Outstanding, February 28, 2025	800,000	0.10
No activity	-	-
Outstanding, November 30, 2025	800,000	0.10

The following table summarizes the stock options outstanding and exercisable as at November 30, 2025 as follows:

Exercise price	Number of options	Exercisable	Expiry date
\$ 0.10	800,000	-	July 27, 2026

Warrants

During the nine months ended November 30, 2025 and 2024, the Company did not issue any warrants.

On July 27, 2021, the Company issued 755,000 non-transferable common share purchase warrants to the Agent on completion of the IPO, entitling the Agent and members of its selling group to purchase 755,000 common shares at \$0.10 per common share until July 27, 2023. The fair value of the Agent Warrants was \$53,856 and was estimated using the Black-Scholes pricing model with the following assumptions:

Risk free interest rate	1.48%
Expected life	2 years
Expected volatility	149%
Expected dividends	0%

On July 27, 2023, the 755,000 agent warrants expired unexercised. As at November 30, 2025 and 2024, the Company did not have any warrants outstanding.

CPC Escrow Agreement

Seed shares issued below the IPO price, shares acquired from treasury by non-arm's length parties to the CPC and CPC stock options and shares issued on exercise of stock options, which were granted before the IPO and at an exercise price less than the IPO price, are all subject to a CPC Escrow Agreement. Under the CPC Escrow Agreement, 25% of the escrowed common shares will be released from escrow on the issuance of the Final Exchange Bulletin (the "Initial Release") and an additional 25% will be released on the dates 6, 12, and 18 months following the Initial Release. Shares acquired by the Pro Group at or above the IPO price and shares acquired by a Control Person in the secondary market are not subject to the CPC Escrow Agreement. 7,630,000 common shares and 800,000 stock options have been deposited in escrow pursuant to the CPC Escrow Agreement.

Related Party Transactions

Related parties include the Board of Directors, close family members and enterprises which are controlled by these individuals as well as persons performing similar functions.

During the nine months ended November 30, 2025 and 2024, there were no related party transactions. There was no compensation to key management personnel. As at November 30, 2025, \$21 (2024 - \$471) was owed to the Chief Executive Officer of the Company.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Financial Instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership.

Financial assets and liabilities are offset and the net amount is reported in the balance sheet when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously.

i) Financial assets

The Company adopted IFRS 9, Financial Instruments, on its incorporation. IFRS 9 replaces International Accounting Standards (IAS) 39, Financial Instruments: Recognition and Measurement. Classification

The Company classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income (OCI) or through profit or loss); and
- those to be measured at amortized cost.

The classification depends on the Company's business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses are either recorded in profit or loss or OCI.

At present, the Company classifies all financial assets as held at amortized cost. Cash and cash equivalents is classified as a financial asset.

Measurement

At initial recognition, the Company measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to the acquisition of the financial asset.

Transaction costs of financial assets carried at FVTPL are expensed in profit or loss. Financial assets are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.

Subsequent measurement of financial assets depends on their classification. There are three measurement categories under which the Company classifies its financial assets:

- Amortized cost: Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. A gain or loss on a debt investment that is subsequently measured at amortized cost is recognized in profit or loss when the asset is derecognized or impaired. Interest income from these financial assets is included as finance income using the effective interest rate method.
- Fair value through OCI (FVOCI): Debt instruments that are held for collection of contractual cash flows and for selling the debt instruments, where the assets' cash flows represent solely payments of principal and interest, are measured at FVOCI. Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains and losses, interest revenue, and foreign exchange gains and losses which are recognized in profit or loss. When the debt instrument is derecognized, the cumulative gain or loss previously recognized in OCI is reclassified from equity to profit or loss and recognized in other gains (losses). Interest income from these debt instruments is included as finance income using the effective interest rate method.
- Fair value through profit or loss: Assets that do not meet the criteria for amortized cost or FVOCI are measured at FVTPL. A gain or loss on an investment that is subsequently measured at FVTPL is recognized in profit or loss and presented net as revenue in the statement of loss and comprehensive loss in the period in which it arises.

ii) Financial liabilities

A financial liability is classified as at FVTPL if it is classified as held-for-trading or is designated as such on initial recognition. Directly attributable transaction costs are recognized in profit or loss as incurred.

The fair value changes to financial liabilities at FVTPL are presented as follows: where the Company optionally designates financial liabilities at FVTPL the amount of change in the fair value that is attributable to changes in the credit risk of the liability is presented in OCI; and the remaining amount of the change in the fair value is presented in profit or loss. The Company does not designate any financial liabilities at FVTPL.

Other non-derivative financial liabilities are initially measured at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method.

At present, the Company classifies all of its financial liabilities as held at amortized cost. These financial liabilities are classified as current liabilities as the payment is due within 12 months.

Financial Risk Management

Capital Management

The Company's objective when managing capital is to maintain its ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. The Company includes share capital in the definition of capital.

The Company's primary objective with respect to its capital management is to ensure that it has sufficient cash resources to fund the identification and evaluation of potential acquisitions. To secure the additional capital necessary to pursue these plans, the Company may attempt to raise additional funds through the issuance of equity or by securing strategic partners.

Cash Restrictions

The proceeds raised from the issuance of common shares may only be used to identify and evaluate assets or businesses for future investment, with the exception that not more than \$3,000 per month may be used for administrative and general expenses of the Company. These restrictions apply until completion of a Qualifying Transaction by the Company as defined under the Exchange Policy 2.4.

Risk Disclosures and Fair Values

The Company's financial instruments, consisting of cash and cash equivalents and accounts payable and accrued liabilities, approximate fair values due to the relatively short-term maturities of the instruments. It is management's opinion that the Company is not exposed to significant interest or currency risks arising from these financial instruments.

Liquidity Risk

As at November 30, 2025, the Company had accounts payable and accrued liabilities of \$41 (2024 - \$472) due within 12 months and had cash and cash equivalents of \$661,603 (2024 - \$696,081) to meet its current obligations. As a result, the Company has minimal liquidity risk.

Credit Risk

Credit risk is the risk of loss associated with the counterparty's inability to fulfill its payment obligations. The Company limits its exposure to credit loss for cash and cash equivalents by placing its cash and cash equivalents with a major financial institution. The Company believes it has no significant credit risk.

Significant Accounting Judgments, Estimates and Assumptions

The preparation of consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities.

The estimates and associated assumptions are based on anticipations and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods. There have been no significant judgments made by management in the application of IFRS that have a significant effect on these consolidated financial statements.

Investor Relations Activities

The Company does not have any investor relations arrangements.

Outstanding Share Data

The Company's authorized share capital is:

- i. Unlimited Class A Common Shares without par value; and
- ii. Unlimited Class B Preferred Shares without par value

As at November 30, 2025, there were 15,000,000 (2024 – 15,000,000) common shares issued and outstanding, 800,000 (2024 – 800,000) stock options outstanding, which are exercisable to acquire one common share at a price of \$0.10 any time prior to July 27, 2026 and Nil (2024 – Nil) warrants outstanding.

As at the date of this report, there were 15,000,000 common shares issued and outstanding, 800,000 stock options outstanding, which are exercisable to acquire one common share at a price of \$0.10 any time prior to July 27, 2026 and nil warrants outstanding.

Corporate Governance

The Company's Board of Directors substantially follow the recommended corporate governance guidelines for public companies to ensure transparency and accountability to shareholders. During the year ended February 29, 2024, Joerg Schweizer resigned as a director of the company without replacement.

The current Board is comprised of 4 individuals, Darren Tindale, Greg Clough, Ashvani Guglani and Jeff Tindale. Greg Clough, Ashvani Guglani and Jeff Tindale are neither executive officers nor employees of the Company and are unrelated in that they are independent of management. The Audit Committee is comprised of 3 directors, Darren Tindale, Greg Clough and Jeff Tindale. Greg Clough and Jeff Tindale are independent of management.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this MD&A are forward-looking statements or forward-looking information (collectively “forward-looking statements”) within the meaning of applicable securities legislation. We are hereby providing cautionary statements identifying important factors that could cause the actual results to differ materially from those projected in the forward-looking statements. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements.

Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The Company believes that the assumptions and expectations reflected in such forward-looking information are reasonable.

While the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect. By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, which contribute to the possibility that the predicted outcomes may not occur or may be delayed.

Readers are cautioned that the foregoing lists of factors are not exhaustive.

The forward-looking statements in this MD&A are based on the reasonable beliefs, expectations and opinions of management on the date of this MD&A. Although we have attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There is no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.